The Use of Biochemical Analyzes to Monitor the Development of Wounds

NCT ID: NCT04507724

Last Updated: 2021-05-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

41 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-10-19

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic wounds represent a growing challenge in medical care.

Part 1: The aim of this part of the study was to collect wound swabs and to answer the question whether the rapid diagnostic tool using enzyme activities can display an infection prematurely. This means that an increased enzyme activity (especially MPO, NHE, LYS, gelatinase, pH) measured overed 3 days, would indicate a change in the wound bed (infection, Inflammation) earlier than the regularly performed clinical assessment.

Part 2: The aim of this part of the study was to evaluate (I) the possibility of wound fluid acquisition by means of an "additional collector" during ongoing NPWT and to answer if (II) this secretion can be biochemically analyzed for enzyme activities in order to be able to detect a change in the wound situation at an early stage.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is composed of two parts, which run independently of each other. However, in both parts the course of the wounds is analyzed.

Part 1: Two wound swabs are taken. One used for routinely performed microbiological analysis and the second will be used for biochemical analysis (enzyme activities). The aim of the wound swabs is to answer the question whether the rapid diagnostic tool used in the examination can display an infection prematurely or not. This means that an increased enzyme activity (especially MPO, NHE, LYS, gelatinase, pH) would indicate a change in the wound bed (infection, inflammation) earlier than the regular clinical assessment. These wound swabs are expected to function as an improvement of the biochemical assays or rather of the technology concerning sensitivity and specificity of, for example, the pH number, the MPO, the LYS, the gelatinase and the elastase. In addition to that, the correlation between the Enzyme activities and the course of the infection will be examined. This technology is supposed to be later used as an early infection diagnostic tool in wound fluids. The followup of this testing system is a crucial prerequisite for the application of the technology in VAC therapy (part 2).

Part 2: The findings of this examination will be used to investigate the applicability of the developed in-vitro early infection diagnostic tool in negative-pressure therapy (VAC therapy; vacuum assisted closure).

Patients of the plastic surgery with a NPWT are included in this prospective study. Before the NPWT will be applied, two swabs (biochemical and microbiological analysis) of the wounds will be taken. After installation of the dressing, the connecting tube between the wound and the vacuum-generating device will be cut and an "additional collector" will be inserted. This collector will be changed daily and afterwards the concentrations of enzymes (lysozyme, elastase, myeloperoxidase) will be biochemically analyzed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Wound Wound Infection Wound Contamination Diagnostic Techniques and Procedures Negative Pressure Wound Therapy Biomarker

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* signed informed consent
* older than 18 years old
* open wound of varying etiology
* VAC therapy (KCI) (part 2)

Exclusion Criteria

* under 18 years old
* pregnant women
* less than three measurement data (less than three swabs) = part 1
* VAC-instill therapy = part 2
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Qualizyme Diagnostics GmbH & Co KG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Christina Helene Wolfsberger

Sub-Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Schintler, Prof.

Role: PRINCIPAL_INVESTIGATOR

Medical University of Graz

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Division of Plastic, Aesthetic and Reconstructive Surgery, Department of Surgery, Medical University of Graz

Graz, , Austria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria

References

Explore related publications, articles, or registry entries linked to this study.

McDaniel JC, Roy S, Wilgus TA. Neutrophil activity in chronic venous leg ulcers--a target for therapy? Wound Repair Regen. 2013 May-Jun;21(3):339-51. doi: 10.1111/wrr.12036. Epub 2013 Mar 28.

Reference Type BACKGROUND
PMID: 23551462 (View on PubMed)

Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Repair Regen. 2000 Jan-Feb;8(1):13-25. doi: 10.1046/j.1524-475x.2000.00013.x.

Reference Type BACKGROUND
PMID: 10760211 (View on PubMed)

Ladwig GP, Robson MC, Liu R, Kuhn MA, Muir DF, Schultz GS. Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair Regen. 2002 Jan-Feb;10(1):26-37. doi: 10.1046/j.1524-475x.2002.10903.x.

Reference Type BACKGROUND
PMID: 11983004 (View on PubMed)

Yager DR, Zhang LY, Liang HX, Diegelmann RF, Cohen IK. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J Invest Dermatol. 1996 Nov;107(5):743-8. doi: 10.1111/1523-1747.ep12365637.

Reference Type BACKGROUND
PMID: 8875960 (View on PubMed)

Izadi K, Ganchi P. Chronic wounds. Clin Plast Surg. 2005 Apr;32(2):209-22. doi: 10.1016/j.cps.2004.11.011.

Reference Type BACKGROUND
PMID: 15814118 (View on PubMed)

Argenta LC, Morykwas MJ. Vacuum-assisted closure: a new method for wound control and treatment: clinical experience. Ann Plast Surg. 1997 Jun;38(6):563-76; discussion 577.

Reference Type BACKGROUND
PMID: 9188971 (View on PubMed)

James GA, Swogger E, Wolcott R, Pulcini Ed, Secor P, Sestrich J, Costerton JW, Stewart PS. Biofilms in chronic wounds. Wound Repair Regen. 2008 Jan-Feb;16(1):37-44. doi: 10.1111/j.1524-475X.2007.00321.x. Epub 2007 Dec 13.

Reference Type BACKGROUND
PMID: 18086294 (View on PubMed)

Steenvoorde P, van Engeland A, Oskam J. Vacuum-assisted closure therapy and oral anticoagulation therapy. Plast Reconstr Surg. 2004 Jun;113(7):2220-1. doi: 10.1097/01.prs.0000123603.32963.11. No abstract available.

Reference Type BACKGROUND
PMID: 15253223 (View on PubMed)

Morykwas MJ, Argenta LC, Shelton-Brown EI, McGuirt W. Vacuum-assisted closure: a new method for wound control and treatment: animal studies and basic foundation. Ann Plast Surg. 1997 Jun;38(6):553-62. doi: 10.1097/00000637-199706000-00001.

Reference Type BACKGROUND
PMID: 9188970 (View on PubMed)

Huang C, Leavitt T, Bayer LR, Orgill DP. Effect of negative pressure wound therapy on wound healing. Curr Probl Surg. 2014 Jul;51(7):301-31. doi: 10.1067/j.cpsurg.2014.04.001. Epub 2014 Apr 26.

Reference Type BACKGROUND
PMID: 24935079 (View on PubMed)

Nuutila K, Yang L, Broomhead M, Proppe K, Eriksson E. Novel negative pressure wound therapy device without foam or gauze is effective at -50 mmHg. Wound Repair Regen. 2019 Mar;27(2):162-169. doi: 10.1111/wrr.3. Epub 2018 Oct 31.

Reference Type BACKGROUND
PMID: 30378215 (View on PubMed)

Isago T, Nozaki M, Kikuchi Y, Honda T, Nakazawa H. Effects of different negative pressures on reduction of wounds in negative pressure dressings. J Dermatol. 2003 Aug;30(8):596-601. doi: 10.1111/j.1346-8138.2003.tb00441.x.

Reference Type BACKGROUND
PMID: 12928528 (View on PubMed)

Fleischmann W, Russ M, Westhauser A, Stampehl M. [Vacuum sealing as carrier system for controlled local drug administration in wound infection]. Unfallchirurg. 1998 Aug;101(8):649-54. doi: 10.1007/s001130050318. German.

Reference Type BACKGROUND
PMID: 9782769 (View on PubMed)

Timmers MS, Graafland N, Bernards AT, Nelissen RG, van Dissel JT, Jukema GN. Negative pressure wound treatment with polyvinyl alcohol foam and polyhexanide antiseptic solution instillation in posttraumatic osteomyelitis. Wound Repair Regen. 2009 Mar-Apr;17(2):278-86. doi: 10.1111/j.1524-475X.2009.00458.x.

Reference Type BACKGROUND
PMID: 19320897 (View on PubMed)

Blokhuis-Arkes MH, Haalboom M, van der Palen J, Heinzle A, Sigl E, Guebitz G, Beuk R. Rapid enzyme analysis as a diagnostic tool for wound infection: Comparison between clinical judgment, microbiological analysis, and enzyme analysis. Wound Repair Regen. 2015 May-Jun;23(3):345-52. doi: 10.1111/wrr.12282. Epub 2015 Jun 19.

Reference Type BACKGROUND
PMID: 25816836 (View on PubMed)

Hasmann A, Wehrschuetz-Sigl E, Marold A, Wiesbauer H, Schoeftner R, Gewessler U, Kandelbauer A, Schiffer D, Schneider KP, Binder B, Schintler M, Guebitz GM. Analysis of myeloperoxidase activity in wound fluids as a marker of infection. Ann Clin Biochem. 2013 May;50(Pt 3):245-54. doi: 10.1258/acb.2011.010249.

Reference Type BACKGROUND
PMID: 23404930 (View on PubMed)

Hasmann A, Gewessler U, Hulla E, Schneider KP, Binder B, Francesko A, Tzanov T, Schintler M, Van der Palen J, Guebitz GM, Wehrschuetz-Sigl E. Sensor materials for the detection of human neutrophil elastase and cathepsin G activity in wound fluid. Exp Dermatol. 2011 Jun;20(6):508-13. doi: 10.1111/j.1600-0625.2011.01256.x. Epub 2011 Apr 13.

Reference Type BACKGROUND
PMID: 21488974 (View on PubMed)

Hasmann A, Wehrschuetz-Sigl E, Kanzler G, Gewessler U, Hulla E, Schneider KP, Binder B, Schintler M, Guebitz GM. Novel peptidoglycan-based diagnostic devices for detection of wound infection. Diagn Microbiol Infect Dis. 2011 Sep;71(1):12-23. doi: 10.1016/j.diagmicrobio.2010.09.009. Epub 2011 Mar 9.

Reference Type BACKGROUND
PMID: 21388768 (View on PubMed)

Klebanoff SJ. Myeloperoxidase. Proc Assoc Am Physicians. 1999 Sep-Oct;111(5):383-9. doi: 10.1111/paa.1999.111.5.383.

Reference Type BACKGROUND
PMID: 10519157 (View on PubMed)

Schiffer D, Blokhuis-Arkes M, van der Palen J, Sigl E, Heinzle A, Guebitz GM. Assessment of infection in chronic wounds based on the activities of elastase, lysozyme and myeloperoxidase. Br J Dermatol. 2015 Dec;173(6):1529-31. doi: 10.1111/bjd.13896. Epub 2015 Oct 29. No abstract available.

Reference Type BACKGROUND
PMID: 25965963 (View on PubMed)

Heinzle A, Papen-Botterhuis NE, Schiffer D, Schneider KP, Binder B, Schintler M, Haaksman IK, Lenting HB, Gubitz GM, Sigl E. Novel protease-based diagnostic devices for detection of wound infection. Wound Repair Regen. 2013 May-Jun;21(3):482-9. doi: 10.1111/wrr.12040. Epub 2013 Apr 29.

Reference Type BACKGROUND
PMID: 23627267 (View on PubMed)

Schiffer D, Tegl G, Heinzle A, Sigl E, Metcalf D, Bowler P, Burnet M, Guebitz GM. Enzyme-responsive polymers for microbial infection detection. Expert Rev Mol Diagn. 2015;15(9):1125-31. doi: 10.1586/14737159.2015.1061935. Epub 2015 Jul 16.

Reference Type BACKGROUND
PMID: 26184576 (View on PubMed)

Tegl G, Schiffer D, Sigl E, Heinzle A, Guebitz GM. Biomarkers for infection: enzymes, microbes, and metabolites. Appl Microbiol Biotechnol. 2015 Jun;99(11):4595-614. doi: 10.1007/s00253-015-6637-7. Epub 2015 May 9.

Reference Type BACKGROUND
PMID: 25952112 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NPWW

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.